Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430846 · ClinicalTrials.gov registry record · Phase 1
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00430846 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 45 participants.
The verdict
NCT00430846, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.
Interventions
- DRUG SGN-35
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430846
The ClinicalTrials.gov registry entry for NCT00430846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-35 is the first listed.
NCT00430846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430846 about?
NCT00430846 is a clinical study titled "Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies". Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies. This is a single-arm, open-label, Phase I dose escalation study designed to define the MTD, PK, immunogenicity and anti-tumor activity of S...
What is the current status of trial NCT00430846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2006-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00430846?
The interventions under investigation include: SGN-35 (DRUG).
Who is sponsoring clinical trial NCT00430846?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.